Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.59 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPY4R | P50391 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.55 |
| ▸ | GLP1R | P43220 | 11/20 | 0.54 |
| ▸ | GCGR | P47871 | 7/20 | 0.54 |
| ▸ | GIPR | P48546 | 7/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | CALCA | P06881 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523602 | 0.96 | NPY1R (0.58) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30553959 | 0.94 | CXCR4 (0.56) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30789042 | 0.89 | CXCR4 (0.63) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30437221 | 0.86 | NPY2R (0.70) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29412272 | 0.86 | CXCR4 (0.66) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30914561 | 0.85 | MAPK8 (0.51) | NPY1RNPY2RNPY4RNPY5RMAPK8 | |
| SCHEMBL31232459 | 0.85 | NPY1R (0.59) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30607423 | 0.85 | NPY2R (0.69) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30536327 | 0.83 | NPY2R (0.72) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL31073511 | 0.83 | CXCR4 (0.61) | NPY1RNPY2RNPY4RNPY5RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156973-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2024-05-16 | — | — | US | disclosed |
| CN-116426508-A | Recombinant lysyl endopeptidase mutant and application thereof | 重庆艾美迪生物科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156973-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | SOST, BMP2, BMP6 | NPY1R 1212/4885NPY2R 1229/4885NPY4R 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.